Suppr超能文献

印度实施免费抗逆转录病毒治疗方案十年后出现的 HIV 耐药性:综述。

HIV drug resistance following a decade of the free antiretroviral therapy programme in India: A review.

机构信息

HIV Drug Resistance Laboratory, National AIDS Research Institute (ICMR), Pune, India; Department of Microbiology, Armed Forces Medical College, Pune, India.

HIV Drug Resistance Laboratory, National AIDS Research Institute (ICMR), Pune, India; Symbiosis International University, Lavale, Pune, India.

出版信息

Int J Infect Dis. 2018 Jan;66:33-41. doi: 10.1016/j.ijid.2017.10.020. Epub 2017 Nov 8.

Abstract

OBJECTIVE

The objective of this review was to assess the burden of HIV drug resistance mutations (DRM) in Indian adults exposed to first-line antiretroviral therapy (ART) as per national guidelines.

METHODS

An advanced search of the published literature on HIV drug resistance in India was performed in the PubMed and Scopus databases. Data pertaining to age, sex, CD4 count, viral load, and prevalence of nucleoside reverse transcriptase inhibitor (NRTI)/non-nucleoside reverse transcriptase inhibitor (NNRTI) DRM were extracted from each publication. Year-wise Indian HIV-1 reverse transcriptase (RT) sequences were retrieved from the Los Alamos HIV database and mutation analyses were performed. A time trend analysis of the proportion of sequences showing NRTI resistance mutations among individuals exposed to first-line ART was conducted.

RESULTS

Overall, 23 studies (1046 unique RT sequences) were identified indicating a prevalence of drug resistance to NRTI and NNRTI. The proportion of RT sequences with any DRM, any NRTI DRM, and any NNRTI DRM was 78.39%, 68.83%, and 73.13%, respectively. The temporal trend analysis of individual DRM from sequences retrieved during 2004-2014 indicated a rising trend in K65R mutations (p=0.013).

CONCLUSIONS

Although the overall burden of resistance against first-line ART agents remained steady over the study decade, periodic monitoring is essential. There is the need to develop an HIV-1 subtype C-specific resistance database in India.

摘要

目的

本综述旨在评估按照国家指南接受一线抗逆转录病毒疗法(ART)的印度成人中 HIV 耐药突变(DRM)的负担。

方法

在 PubMed 和 Scopus 数据库中对印度 HIV 耐药性的已发表文献进行了高级搜索。从每份出版物中提取有关年龄、性别、CD4 计数、病毒载量和核苷逆转录酶抑制剂(NRTI)/非核苷逆转录酶抑制剂(NNRTI)DRM 流行率的数据。从 Los Alamos HIV 数据库中检索了逐年的印度 HIV-1 逆转录酶(RT)序列,并进行了突变分析。对暴露于一线 ART 的个体中显示 NRTI 耐药突变的序列比例进行了时间趋势分析。

结果

总共确定了 23 项研究(1046 个独特的 RT 序列),表明对 NRTI 和 NNRTI 的耐药率。具有任何 DRM、任何 NRTI DRM 和任何 NNRTI DRM 的 RT 序列的比例分别为 78.39%、68.83%和 73.13%。从 2004-2014 年期间检索到的序列中的个体 DRM 的时间趋势分析表明,K65R 突变呈上升趋势(p=0.013)。

结论

尽管在研究的十年中,针对一线 ART 药物的耐药总体负担保持稳定,但仍需要定期监测。印度需要开发针对 HIV-1 亚型 C 的耐药性数据库。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验